NCT05497414

Brief Summary

This study will investigate how sleep and mood are related in patients with depression and in healthy controls. It will use MRI-based measures of brain function to determine how neural systems are modulated by sleep and sleep deprivation, and its links to mood in depression.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 31, 2022

Completed
24 days until next milestone

First Submitted

Initial submission to the registry

February 24, 2022

Completed
6 months until next milestone

First Posted

Study publicly available on registry

August 11, 2022

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2024

Completed
Last Updated

August 29, 2022

Status Verified

August 1, 2022

Enrollment Period

2.4 years

First QC Date

February 24, 2022

Last Update Submit

August 26, 2022

Conditions

Outcome Measures

Primary Outcomes (6)

  • Change in fMRI signals in thalamus region of interest (ROI) from baseline to post intervention

    fMRI signal (units: %)

    Through study completion (approximately 1 month)

  • Change in fMRI signals in amygdala ROI from baseline to post intervention

    fMRI signal (units: %)

    Through study completion (approximately 1 month)

  • Change in tasked evoked responses in amygdala ROI from baseline to post intervention

    Task evoked responses in amygdala ROI (units: %)

    Through study completion (approximately 1 month)

  • Change in cerebrospinal fluid (CSF) flow measurements from baseline to post intervention

    Fluid flow measured with MRI (units: %)

    Through study completion (approximately 1 month)

  • Change in Montgomery-Asberg Depression Rating from baseline to post intervention

    Mood scores, measured on scale of 0-60

    Through study completion (approximately 1 month)

  • Change in whole-brain voxelwise fMRI activity from baseline to post intervention

    fMRI measure of hemodynamics (units: %)

    Through study completion (approximately 1 month)

Secondary Outcomes (15)

  • Change in EEG dynamics from baseline to post intervention

    Through study completion (approximately 1 month)

  • Change in dot probe task performance from baseline to post intervention

    Through study completion (approximately 1 month)

  • Change in blood biomarkers of C-reactive protein from baseline to post intervention

    Through study completion (approximately 1 month)

  • Change in blood levels of Interleukin 6 from baseline to post intervention

    Through study completion (approximately 1 month)

  • Change in Magnetic Resonance Spectroscopy (MRS) measurement of lactate from baseline to post intervention

    Through study completion (approximately 1 month)

  • +10 more secondary outcomes

Study Arms (2)

Sleep deprived

EXPERIMENTAL

Overnight sleep deprivation

Behavioral: Sleep deprivation

Rested

NO INTERVENTION

Well-rested sleep pattern

Interventions

Overnight sleep deprivation.

Sleep deprived

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult aged 18-80
  • \- Current diagnosis of major depressive disorder

You may not qualify if:

  • Must not have ferrous metal implanted in head or body
  • Must have no history of major head trauma
  • Must not have implanted electronic devices (e.g., pacemaker, neurostimulator)
  • Must not be pregnant, suspect they are pregnant, or seeking to become pregnant
  • Must not be claustrophobic
  • Must have no piercings or jewelry that cannot be removed
  • Weight less than 250 pounds
  • No lifetime history of schizophrenia or any other psychosis disorder, substantial intellectual disability, bipolar disorder, post-traumatic stress disorder or obsessive compulsive disorder
  • No alcohol or substance abuse or dependence within the past 6 months
  • No significant personality dysfunction
  • Must not indicate significant suicide risk.
  • Must not be taking medications that significantly affect sleep, psychiatric function, blood/vascular function, or anti-inflammatory medications (other than minor NSAID use).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Boston University

Boston, Massachusetts, 02215, United States

RECRUITING

MeSH Terms

Conditions

Depressive Disorder, Major

Condition Hierarchy (Ancestors)

Depressive DisorderMood DisordersMental Disorders

Study Officials

  • Laura Lewis, PhD

    Boston University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Dabriel Zimmerman, BS

CONTACT

Stephanie Anakwe, BS

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
FACTORIAL
Model Details: Two groups (healthy vs major depression) are studied under two conditions (rested vs sleep deprivation).
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 24, 2022

First Posted

August 11, 2022

Study Start

January 31, 2022

Primary Completion

July 1, 2024

Study Completion

July 1, 2024

Last Updated

August 29, 2022

Record last verified: 2022-08

Locations